References and Notes
1a
Smaill JB.
Rewcastle GW.
Bridges AJ.
Zhou H.
Showalter HDH.
Fry DW.
Nelson JM.
Sherwood V.
Elliott WL.
Vincent PW.
DeJohn DE.
Loo JA.
Greis KD.
Chan OH.
Reyner EL.
Lipka E.
Denny WA.
J. Med. Chem.
2000,
43:
3199
1b
Eckhardt M.
Langkopf E.
Mark M.
Tadayyon M.
Thomas L.
Nar H.
Pfrengle W.
Guth B.
Lotz R.
Sieger P.
Fuchs H.
Himmelsbach F.
J.
Med. Chem.
2007,
50:
6450
1c
Bavetsias V.
Skelton LA.
Yafai F.
Mitchell F.
Wilson SC.
Allan B.
Jackman AL.
J.
Med. Chem.
2002,
45:
3692
1d
Tsou H.-R.
Mamuya N.
Johnson
BD.
Reich MF.
Gruber BC.
Ye F.
Nilakantan R.
Shen R.
Discafani C.
DeBlanc R.
Davis R.
Koehn
FE.
Greenberger LM.
Wang Y.-F.
Wissner A.
J. Med. Chem.
2001,
44:
2719
1e
Gackenheimer SL.
Schaus
JM.
Gehlert DR.
J. Pharmacol. Exp.
Ther.
1995,
274:
1558
1f
Dempcy RO.
Skibo EB.
Biochemistry
1991,
30:
8480
2a
Connolly DJ.
Cusack D.
O’Sullivan TP.
Guiry
PJ.
Tetrahedron
2005,
61:
10153
2b
Hill MD.
Movassaghi M.
Chem.
Eur. J.
2008,
14:
6836
2c
Nikpour F.
Paibast T.
Chem. Lett.
2005,
34:
1438
3a
Wada A.
Yamamoto H.
Ohki K.
Nagai S.
Kanatomo S.
J. Heterocycl. Chem.
1992,
29:
911
3b
Kim SK.
Russel KC.
J. Org. Chem.
1998,
63:
8229
4a
Cikotiene I.
Buksnaitiene R.
Brukstus A.
Chem. Heterocycl. Comp.
2007,
43:
515
4b
Cikotiene I.
Morkunas M.
Rudys S.
Buksnaitiene R.
Brukstus A.
Synlett
2008, 2799
5
Cikotiene I.
Morkunas M.
Motiejaitis D.
Rudys S.
Brukstus A.
Synlett
2008,
1693
6
Cikotiene I.
Pudziuvelyte E.
Brukstus A.
Tumkevicius S.
Tetrahedron
2007,
63:
8145
7 Crystal structure analysis for 3a: C21H21N3O2S,
Mr = 379.47 g mol-¹,
monoclinic, space group P21/a, a = 7.5916
(2), b = 19.0791 (4), c = 13.2219 (4) Å, α = 90.00˚, β = 94.3120
(9)˚, γ = 90.00˚, V = 1909.65 (9) ų, ρ = 1.320 g/cm³,
F(000) = 800. X-ray diffraction data were collected on
a Nonius Kappa CCD diffractometer at 293 K using graphite-monochromated
Mo-Kα radiation (λ = 0.71073 Å). Structure 3a was solved by direct methods with SIR97 program¹¹ and
refined by full-matrix least squares techniques with anisotropic
non-hydrogen atoms. Hydrogen atoms were refined in the riding model.
The refinement calculations were carried out with the help of SHELX97 program.¹² ORTEP¹³ view
of the molecule is shown in Figure
[¹]
.
Crystallographic data for structure 3a have
been deposited at the Cambridge Crystallographic Data Centre (CCDC
number 703429).
8a
Scott GP.
J. Am. Chem. Soc.
1953,
75:
6332
8b
Dimroth K.
Lenke G.
Chem. Ber.
1956,
89:
2608
9
Typical Procedure
for the Preparation of 2,4-Disub-stituted 7-Aryl-6-methoxycarbonylquinazolines
3a-o: To a solution of the corresponding 6-arylethynylpyrimidine-5-carbaldehyde 1a-o (0.3
mmol) in methanol (5 mL) a solution of potassium salt of methyl
mercaptoacetate, prepared from potassium (11.7 mg, 0.3 mmol), methyl mercaptoacetate
(31.8 mg, 0.3 mmol) and methanol (3 mL) was added. The resulting
reaction mixture was stirred for 2 h at r.t. The solvent was evaporated
under reduced pressure, the residue was washed with H2O,
filtered and recrystallized to give compounds 3a-o.
6-Methoxycarbonyl-2-methylthio-7-phenyl-4-pyrroli-dinoquinazoline
(3a): yield: 86%; mp 185-187 ˚C
(from MeOH). IR (KBr): 1708 (C=O) cm-¹. ¹H
NMR (300 MHz, DMSO-d
6): δ = 2.01 [br
s, 4 H, (CH2)2], 2.54 (s, 3 H, SMe), 3.62
(s, 3 H, OMe), 3.92 [br s, 4 H, N(CH2)2],
7.37-7.47 (m, 5 H, ArH), 7.45 (s, 1 H, CH), 8.64 (s, 1
H, CH). ¹³C NMR (75 MHz, DMSO-d
6): δ = 13.4,
25.0, 50.6, 51.9, 11.9, 125.0, 127.2, 127.6, 127.9, 128.1, 129.2,
139.7, 144.8, 152.9, 157.5, 167.4, 168.7. Anal. Calcd for C21H21N3O2S:
C, 66.47; H, 5.58; N, 11.07. Found: C, 66.37; H, 5.53; N, 11.11.
10 Compounds 2a,b and 3b-o were also fully characterized by IR, ¹H
NMR, ¹³C NMR spectroscopic and microanalytical data.
11
Altomare A.
Burla MC.
Camalli M.
Cascarano GL.
Giacovazzo C.
Guagliardi A.
Moliterni AGG.
Polidori G.
Spagna R.
J. Appl. Crystallogr.
1999,
32:
115
12
Sheldrick GM.
SHELXL97,
Program for the Refinement of Crystal Structures
University
of Göttingen;
Germany:
1997.
13
Johnson CK.
ORTEP-II,
Report ORNL-5138
Oak Ridge National Laboratory;
Oak
Ridge TN (USA):
1976.